--- title: "NG00052 – CLU, A potential endophenotype for AD: Summary Statistics – Deming et al. (2016)" id: "7671" type: "dataset" slug: "ng00052" published_at: "2025-01-21T19:51:42+00:00" modified_at: "2026-03-19T18:08:05+00:00" url: "https://dss.niagads.org/datasets/ng00052/" markdown_url: "https://dss.niagads.org/datasets/ng00052.md" excerpt: "All data provided in this dataset are open access and are available publicly in the “Open Access Dataset” tab." taxonomy_dataset_categories: - "1000G Phase1α" - "AD" - "Data Type" - "Disease" - "Illumina Human610-Quad" - "Illumina OmniExpress" - "Imputation" - "Open Access" - "Open and Controlled Access Data" - "Platform" - "Summary Statistics" --- ## Overview All data provided in this dataset are open access and are available publicly in the “Open Access Dataset” tab. #### Description This dataset contains summary statistics of a genome-wide association study to understand the role of Clusterin (CLU – Endophenotype for AD) in Alzheimer’s Disease. The GWAS data for these summary statistics can be accessed at [NG00050](https://dss.niagads.org/datasets/ng00050/) . The dataset is comprised of information from 50 individuals, the additional 350 subjects are available through the [NG00035](https://dss.niagads.org/datasets/ng00035/) dataset. Imputed data for the 50 individuals consists of 6,015,512 SNPS using 1000 Genome data (Phase 1 α) CEU (build 37) as a reference. This dataset is part of the Knight ADRC Collection. Other datasets in this collection can be found at: [https://www.niagads.org/knight-adrc-collection](https://www.niagads.org/knight-adrc-collection) . This dataset was originally published on the NIAGADS archive site on 08/10/2016 and was moved to DSS on 02/21/2025. #### Available Filesets | Name | Accession | Latest Release | Description | | --- | --- | --- | --- | | Knight GWAS of CLU: Summary Statistics (open access) | fsa000124 | NG00052.v1 | Summary Statisitcs | View the [File Manifest](https://st1.niagads.org/portal/download-public/NG00052.v1/fm) for a full list of files released in this dataset. ## Related Studies - [sa000008 - Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight ADRC)](https://dss.niagads.org/studies/sa000008/) The search for novel risk factors for Alzheimer disease relies on access to accurate and deeply phenotyped datasets. The Memory and Aging Project at the Knight-ADRC (Knight ADRC-MAP) collects plasma,… [Learn more](https://dss.niagads.org/studies/sa000008/) ## Acknowledgement ### Acknowledgment statement for any data distributed by NIAGADS: Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging. Use the study-specific acknowledgement statements below (as applicable): ### For investigators using any data from this dataset: Please cite/reference the use of NIAGADS data by including the accession [NG00052](https://archive.niagads.org/datasets/NG00052) . ### For investigators using Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight ADRC) (sa000008) data: This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. **See below for additional dataset specific acknowledgments:** *For use of the ADSP-PHC harmonized phenotypes deposited within dataset, ng00067, use the following statement:* The Memory and Aging Project at the Knight-ADRC (Knight-ADRC), supported by NIH grants R01AG064614, R01AG044546, RF1AG053303, RF1AG058501, U01AG058922 and R01AG064877 to Carlos Cruchaga. The recruitment and clinical characterization of research participants at Washington University was supported by NIH grants P30AG066444, P01AG03991, and P01AG026276. Data collection and sharing for this project was supported by NIH grants RF1AG054080, P30AG066462, R01AG064614 and U01AG052410. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: [https://neurogenomics.wustl.edu/](https://neurogenomics.wustl.edu/) ) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. *For use of ng00050 and ng00052, use the following statement:* This work was supported by Pfizer and grants from the National Institutes of Health (R01-AG044546, P01-AG003991), and the Alzheimer's Association (NIRG-11–200110). This research was conducted while Carlos Cruchaga was a recipient of a New Investigator Award in Alzheimer's disease from the American Federation for Aging Research. Carlos Cruchaga is a recipient of a BrightFocus Foundation Alzheimer's Disease Research Grant (A2013359S). The recruitment and clinical characterization of research participants at Washington University were supported by NIHP50 AG05681, P01 AG03991, and P01 AG026276. Some of the samples used in this study were genotyped by the ADGC and GERAD. ADGC is supported by grants from the NIH (#U01AG032984) and GERAD from the Wellcome Trust (GR082604MA) and the Medical Research Council (G0300429). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace; Merck; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org/) ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. ## Publications - Deming Y. **A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.***Neurobiology of aging. 2016 Jan.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/26545630/) ### Total number of participants: 0